Second, the association of IL-1β with pathogenic PD-L1 regulation functions consistently regardless of EGFR gene status, while the proportion of NSCLC tumors with high PD-L1 expression tends to be lower for patients with activating EGFR mutations than for those wild type for EGFR (47), with mechanisms associated with such mutations appearing to negatively regulate PD-L1 expression. Here, IL1B is linked to non-small cell lung carcinoma.